{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,20]],"date-time":"2026-01-20T04:02:11Z","timestamp":1768881731333,"version":"3.49.0"},"reference-count":26,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,8,6]],"date-time":"2025-08-06T00:00:00Z","timestamp":1754438400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100021856","name":"Ministero dell'Universit\u00e0 e della Ricerca","doi-asserted-by":"publisher","award":["PNC0000007"],"award-info":[{"award-number":["PNC0000007"]}],"id":[{"id":"10.13039\/501100021856","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003407","name":"Ministero dell\u2019Istruzione, dell\u2019Universit\u00e0 e della Ricerca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003407","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009104","name":"University of Modena and Reggio Emilia","doi-asserted-by":"publisher","award":["A.D06@FAR2024_DIP@05FA-CANNAZZA_FARDIP_2024"],"award-info":[{"award-number":["A.D06@FAR2024_DIP@05FA-CANNAZZA_FARDIP_2024"]}],"id":[{"id":"10.13039\/100009104","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Pharmaceutical and Biomedical Analysis"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.jpba.2025.117091","type":"journal-article","created":{"date-parts":[[2025,8,7]],"date-time":"2025-08-07T15:13:12Z","timestamp":1754579592000},"page":"117091","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Non-targeted metabolite characterization in microsomal assay using liquid chromatography coupled to high-resolution mass spectrometry: Application to carisoprodol"],"prefix":"10.1016","volume":"266","author":[{"ORCID":"https:\/\/orcid.org\/0009-0000-0360-8538","authenticated-orcid":false,"given":"Elena","family":"Ferri","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-1769-1555","authenticated-orcid":false,"given":"Cristian","family":"Caprari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria Angela","family":"Vandelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Loretta L.","family":"Del Mercato","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9210-5074","authenticated-orcid":false,"given":"Cinzia","family":"Citti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giuseppe","family":"Cannazza","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jpba.2025.117091_bib1","first-page":"197","article-title":"Carisoprodol intoxication: a comprehensive review","volume":"22","author":"Amin","year":"2019","journal-title":"Crit. Care Shock"},{"key":"10.1016\/j.jpba.2025.117091_bib2","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.drugalcdep.2019.05.025","article-title":"Impact of schedule IV controlled substance classification on carisoprodol utilization in the United States: an interrupted time series analysis","volume":"202","author":"Li","year":"2019","journal-title":"Drug Alcohol Depend."},{"key":"10.1016\/j.jpba.2025.117091_bib3","unstructured":"Carisoprodol - referral | European Medicines Agency (EMA), (2007). \u3008https:\/\/www.ema.europa.eu\/en\/medicines\/human\/referrals\/carisoprodol\u3009 (accessed July 17, 2025)."},{"key":"10.1016\/j.jpba.2025.117091_bib4","unstructured":"WHO Expert Committee on Drug Dependence: Forty-seventh report, (2025). \u3008https:\/\/www.who.int\/publications\/i\/item\/9789240107649\u3009 (accessed July 17, 2025)."},{"key":"10.1016\/j.jpba.2025.117091_bib5","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1093\/jat\/bks018","article-title":"Evaluating the relationship between carisoprodol concentrations and meprobamate formation and Inter-Subject and Intra-Subject variability in urinary excretion data of pain patients","volume":"36","author":"Tse","year":"2012","journal-title":"J. Anal. Toxicol."},{"key":"10.1016\/j.jpba.2025.117091_bib6","unstructured":"Drugs@FDA: FDA-Approved Drugs, (n.d.). \u3008https:\/\/www.accessdata.fda.gov\/scripts\/cder\/daf\/index.cfm?event=overview.process&ApplNo=011792\u3009 (Accessed February 26, 2025)."},{"key":"10.1016\/j.jpba.2025.117091_bib7","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.curtheres.2010.02.003","article-title":"Bioavailability of oral carisoprodol 250 and 350 mg and metabolism to meprobamate: a single-dose crossover study","volume":"71","author":"Simon","year":"2010","journal-title":"Curr. Ther. Res."},{"key":"10.1016\/j.jpba.2025.117091_bib8","doi-asserted-by":"crossref","first-page":"858","DOI":"10.3390\/jcm11030858","article-title":"Single and multiple dose PK-PD characterization for carisoprodol. Part I: pharmacokinetics, metabolites, and 2C19 phenotype influence. Double-blind, Placebo-Controlled clinical trial in healthy volunteers","volume":"11","author":"Calvo","year":"2022","journal-title":"J. Clin. Med."},{"key":"10.1016\/j.jpba.2025.117091_bib9","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1177\/0960327116672912","article-title":"Pharmacokinetic modeling of carisoprodol and meprobamate disposition in adults","volume":"36","author":"Lewandowski","year":"2017","journal-title":"Hum. Exp. Toxicol."},{"key":"10.1016\/j.jpba.2025.117091_bib10","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1002\/cpt.597","article-title":"Clinical pharmacogenetics implementation consortium guideline (CPIC) for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants: 2016 update","volume":"102","author":"Hicks","year":"2017","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.jpba.2025.117091_bib11","unstructured":"L. Dean, M. Kane, Carisoprodol Therapy and CYP2C19 Genotype, in: V.M. Pratt, S.A. Scott, M. Pirmohamed, B. Esquivel, B.L. Kattman, A.J. Malheiro (Eds.), Med. Genet. Summ., National Center for Biotechnology Information (US), Bethesda (MD), 2012. \u3008http:\/\/www.ncbi.nlm.nih.gov\/books\/NBK425390\/\u3009 (accessed February 27, 2025)."},{"key":"10.1016\/j.jpba.2025.117091_bib12","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1007\/s00228-005-0970-1","article-title":"The CYP2C19 genotype and the use of oral contraceptives influence the pharmacokinetics of carisoprodol in healthy human subjects","volume":"61","author":"Bramness","year":"2005","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"10.1016\/j.jpba.2025.117091_bib13","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1097\/00007691-199408000-00001","article-title":"Carisoprodol elimination in humans","volume":"16","author":"Olsen","year":"1994","journal-title":"Ther. Drug Monit."},{"key":"10.1016\/j.jpba.2025.117091_bib14","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1124\/jpet.109.151142","article-title":"Carisoprodol-Mediated modulation of GABAA receptors: in vitro and in vivo studies","volume":"329","author":"Gonzalez","year":"2009","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.jpba.2025.117091_bib15","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/S0022-3565(25)26382-0","article-title":"The metabolic fate of carisoprodol in the dog","volume":"138","author":"Douglas","year":"1962","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.jpba.2025.117091_bib16","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1093\/jat\/27.2.118","article-title":"Simultaneous determination of carisoprodol and acetaminophen in an attempted suicide by liquid Chromatography-Mass spectrometry with positive electrospray ionization","volume":"27","author":"Matsumoto","year":"2003","journal-title":"J. Anal. Toxicol."},{"key":"10.1016\/j.jpba.2025.117091_bib17","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1016\/0006-2952(65)90114-0","article-title":"Structure of the metabolite of carisoprodol, hydroxycarisoprodol","volume":"14","author":"Edelson","year":"1965","journal-title":"Biochem. Pharm."},{"key":"10.1016\/j.jpba.2025.117091_bib18","doi-asserted-by":"crossref","first-page":"S61","DOI":"10.1365\/s10337-004-0244-6","article-title":"Quantitative determination of carisoprodol and its metabolites in equine urine and serum by liquid Chromatography-Tandem mass spectrometry","volume":"59","author":"Skinner","year":"2004","journal-title":"Chromatographia"},{"key":"10.1016\/j.jpba.2025.117091_bib19","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1093\/bioinformatics\/btz695","article-title":"NERDD: a web portal providing access to in silico tools for drug discovery","volume":"36","author":"Stork","year":"2020","journal-title":"Bioinformatics"},{"key":"10.1016\/j.jpba.2025.117091_bib20","unstructured":"Advanced Chemistry Development, Inc., ACD\/ChemSketch (Freeware Version 2024.2.0) Toronto (ON), (2024). \u3008https:\/\/www.acdlabs.com\u3009."},{"key":"10.1016\/j.jpba.2025.117091_bib21","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1021\/acs.chemrestox.0c00224","article-title":"GLORYx: prediction of the metabolites resulting from phase 1 and phase 2 biotransformations of xenobiotics","volume":"34","author":"de Bruyn Kops","year":"2021","journal-title":"Chem. Res. Toxicol."},{"key":"10.1016\/j.jpba.2025.117091_bib22","article-title":"In vitro drug metabolism using liver microsomes","volume":"74","author":"Knights","year":"2016","journal-title":"Curr. Protoc. Pharm."},{"key":"10.1016\/j.jpba.2025.117091_bib23","unstructured":"Thermo Fisher Scientific Inc, Compound Discoverer 3.3 SP3 Waltham (MA): Thermo Fisher Scientific, (2024). \u3008https:\/\/www.thermofisher.com\u3009."},{"key":"10.1016\/j.jpba.2025.117091_bib24","doi-asserted-by":"crossref","DOI":"10.1016\/j.jpba.2022.114731","article-title":"Quantification of the irreversible fibroblast growth factor receptor inhibitor futibatinib by UPLC-MS\/MS: application to the metabolic stability assay in human liver microsomes for the estimation of its in vitro hepatic intrinsic clearance","volume":"214","author":"Tang","year":"2022","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.jpba.2025.117091_bib25","doi-asserted-by":"crossref","first-page":"257","DOI":"10.3390\/pharmaceutics16020257","article-title":"Metabolic stability and metabolite identification of N-Ethyl pentedrone using rat, mouse and human liver microsomes","volume":"16","author":"Godoi","year":"2024","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.jpba.2025.117091_bib26","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1097\/00008571-199610000-00002","article-title":"Formation of meprobamate from carisoprodol is catalysed by CYP2C19","volume":"6","author":"Dal\u00e9n","year":"1996","journal-title":"Pharmacogenetics"}],"container-title":["Journal of Pharmaceutical and Biomedical Analysis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0731708525004327?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0731708525004327?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T02:16:07Z","timestamp":1762308967000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0731708525004327"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":26,"alternative-id":["S0731708525004327"],"URL":"https:\/\/doi.org\/10.1016\/j.jpba.2025.117091","relation":{},"ISSN":["0731-7085"],"issn-type":[{"value":"0731-7085","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Non-targeted metabolite characterization in microsomal assay using liquid chromatography coupled to high-resolution mass spectrometry: Application to carisoprodol","name":"articletitle","label":"Article Title"},{"value":"Journal of Pharmaceutical and Biomedical Analysis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jpba.2025.117091","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"117091"}}